Details for New Drug Application (NDA): 020636
✉ Email this page to a colleague
NDA 020636 describes VIRAMUNE, which is a drug marketed by Boehringer Ingelheim and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the VIRAMUNE profile page.
The generic ingredient in VIRAMUNE is nevirapine. There are twenty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.
The generic ingredient in VIRAMUNE is nevirapine. There are twenty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.
Summary for 020636
| Tradename: | VIRAMUNE |
| Applicant: | Boehringer Ingelheim |
| Ingredient: | nevirapine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020636
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jun 21, 1996 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
